Use of Bacteriophages in Lung Transplantation

Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing numbe...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Manuel López-Meseguer [verfasserIn] Marta Zapata-Ortega [verfasserIn] Cristina Berastegui-Garcia [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	Bacteriophages. Lung transplant. Multi-drug resistant organisms.

Übergeordnetes Werk:	In: Barcelona Respiratory Network Reviews - Publicaciones Permanyer, 2022, 9(2023), 3
Übergeordnetes Werk:	volume:9 ; year:2023 ; number:3

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.23866/BRNRev:2023-M0096

Katalog-ID:	DOAJ101681518

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ101681518
003	DE-627
005	20240414203143.0
007	cr uuu---uuuuu
008	240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.23866/BRNRev:2023-M0096 \|2 doi
035			\|a (DE-627)DOAJ101681518
035			\|a (DE-599)DOAJec3039ef437e4deab69b8cb849b17568
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC705-779
100	0		\|a Manuel López-Meseguer \|e verfasserin \|4 aut
245	1	0	\|a Use of Bacteriophages in Lung Transplantation
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.
650		4	\|a Bacteriophages. Lung transplant. Multi-drug resistant organisms.
653		0	\|a Diseases of the respiratory system
700	0		\|a Marta Zapata-Ortega \|e verfasserin \|4 aut
700	0		\|a Cristina Berastegui-Garcia \|e verfasserin \|4 aut
773	0	8	\|i In \|t Barcelona Respiratory Network Reviews \|d Publicaciones Permanyer, 2022 \|g 9(2023), 3 \|w (DE-627)1827079673 \|x 23857110 \|7 nnns
773	1	8	\|g volume:9 \|g year:2023 \|g number:3
856	4	0	\|u https://doi.org/10.23866/BRNRev:2023-M0096 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 \|z kostenfrei
856	4	0	\|u https://www.brnreviews.com/frame_esp.php?id=237 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2462-3172 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2023 \|e 3

Indexfelder

author_variant	m l m mlm m z o mzo c b g cbg
matchkey_str	article:23857110:2023----::sobceipaeilntas
hierarchy_sort_str	2023
callnumber-subject-code	RC
publishDate	2023
allfields	10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3
spelling	10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3
allfields_unstemmed	10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3
allfieldsGer	10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3
allfieldsSound	10.23866/BRNRev:2023-M0096 doi (DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568 DE-627 ger DE-627 rakwb eng RC705-779 Manuel López-Meseguer verfasserin aut Use of Bacteriophages in Lung Transplantation 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis. Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system Marta Zapata-Ortega verfasserin aut Cristina Berastegui-Garcia verfasserin aut In Barcelona Respiratory Network Reviews Publicaciones Permanyer, 2022 9(2023), 3 (DE-627)1827079673 23857110 nnns volume:9 year:2023 number:3 https://doi.org/10.23866/BRNRev:2023-M0096 kostenfrei https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 kostenfrei https://www.brnreviews.com/frame_esp.php?id=237 kostenfrei https://doaj.org/toc/2462-3172 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2023 3
language	English
source	In Barcelona Respiratory Network Reviews 9(2023), 3 volume:9 year:2023 number:3
sourceStr	In Barcelona Respiratory Network Reviews 9(2023), 3 volume:9 year:2023 number:3
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Bacteriophages. Lung transplant. Multi-drug resistant organisms. Diseases of the respiratory system
isfreeaccess_bool	true
container_title	Barcelona Respiratory Network Reviews
authorswithroles_txt_mv	Manuel López-Meseguer @@aut@@ Marta Zapata-Ortega @@aut@@ Cristina Berastegui-Garcia @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	1827079673
id	DOAJ101681518
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101681518</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414203143.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.23866/BRNRev:2023-M0096</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101681518</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJec3039ef437e4deab69b8cb849b17568</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Manuel López-Meseguer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of Bacteriophages in Lung Transplantation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bacteriophages. Lung transplant. Multi-drug resistant organisms.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Zapata-Ortega</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristina Berastegui-Garcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Barcelona Respiratory Network Reviews</subfield><subfield code="d">Publicaciones Permanyer, 2022</subfield><subfield code="g">9(2023), 3</subfield><subfield code="w">(DE-627)1827079673</subfield><subfield code="x">23857110</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.23866/BRNRev:2023-M0096</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.brnreviews.com/frame_esp.php?id=237</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2462-3172</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2023</subfield><subfield code="e">3</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Manuel López-Meseguer
spellingShingle	Manuel López-Meseguer misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system Use of Bacteriophages in Lung Transplantation
authorStr	Manuel López-Meseguer
ppnlink_with_tag_str_mv	@@773@@(DE-627)1827079673
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC705-779
illustrated	Not Illustrated
issn	23857110
topic_title	RC705-779 Use of Bacteriophages in Lung Transplantation Bacteriophages. Lung transplant. Multi-drug resistant organisms
topic	misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system
topic_unstemmed	misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system
topic_browse	misc RC705-779 misc Bacteriophages. Lung transplant. Multi-drug resistant organisms. misc Diseases of the respiratory system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Barcelona Respiratory Network Reviews
hierarchy_parent_id	1827079673
hierarchy_top_title	Barcelona Respiratory Network Reviews
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1827079673
title	Use of Bacteriophages in Lung Transplantation
ctrlnum	(DE-627)DOAJ101681518 (DE-599)DOAJec3039ef437e4deab69b8cb849b17568
title_full	Use of Bacteriophages in Lung Transplantation
author_sort	Manuel López-Meseguer
journal	Barcelona Respiratory Network Reviews
journalStr	Barcelona Respiratory Network Reviews
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2023
contenttype_str_mv	txt
author_browse	Manuel López-Meseguer Marta Zapata-Ortega Cristina Berastegui-Garcia
container_volume	9
class	RC705-779
format_se	Elektronische Aufsätze
author-letter	Manuel López-Meseguer
doi_str_mv	10.23866/BRNRev:2023-M0096
author2-role	verfasserin
title_sort	use of bacteriophages in lung transplantation
callnumber	RC705-779
title_auth	Use of Bacteriophages in Lung Transplantation
abstract	Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.
abstractGer	Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.
abstract_unstemmed	Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	3
title_short	Use of Bacteriophages in Lung Transplantation
url	https://doi.org/10.23866/BRNRev:2023-M0096 https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568 https://www.brnreviews.com/frame_esp.php?id=237 https://doaj.org/toc/2462-3172
remote_bool	true
author2	Marta Zapata-Ortega Cristina Berastegui-Garcia
author2Str	Marta Zapata-Ortega Cristina Berastegui-Garcia
ppnlink	1827079673
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.23866/BRNRev:2023-M0096
callnumber-a	RC705-779
up_date	2024-07-03T21:57:42.631Z
_version_	1803596713327329280
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101681518</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414203143.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.23866/BRNRev:2023-M0096</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101681518</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJec3039ef437e4deab69b8cb849b17568</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Manuel López-Meseguer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use of Bacteriophages in Lung Transplantation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Bacteriophages (phages) are natural predators of bacteria and are becoming increasingly attractive due to the increase of multidrug-resistant organisms (MDROs), especially prevalent among transplant recipients. Antibiotic resistance is the biggest current threat to global health. An increasing number of infections is becoming harder or almost impossible to treat, carrying high morbidity, mortality and financial cost. The therapeutic use of bacteriophages, viruses that infect and kill bacteria, is well suited to be part of the strategies to combat antibiotic resistance. Infections, in particular those due to bacterial pathogens, are common among transplant candidates and recipients. For lung transplant (LTx) patients this is of paramount relevance, since some of the underlying diseases in LTx present recurrent infection and complex colonization (such as cystic fibrosis or bronchiectasis). Individual case reports and small case series suggest the possible efficacy of phage therapy for the treatment in pre- and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases, so it is reasonable to pursue phage therapy for difficult infections on a compassionate basis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bacteriophages. Lung transplant. Multi-drug resistant organisms.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marta Zapata-Ortega</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cristina Berastegui-Garcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Barcelona Respiratory Network Reviews</subfield><subfield code="d">Publicaciones Permanyer, 2022</subfield><subfield code="g">9(2023), 3</subfield><subfield code="w">(DE-627)1827079673</subfield><subfield code="x">23857110</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.23866/BRNRev:2023-M0096</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ec3039ef437e4deab69b8cb849b17568</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.brnreviews.com/frame_esp.php?id=237</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2462-3172</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2023</subfield><subfield code="e">3</subfield></datafield></record></collection>
score	7.4006443

Nicht das Richtige dabei?

Schreiben Sie uns!

Use of Bacteriophages in Lung Transplantation

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?